Cargando…
South African hypertension practice guideline 2014
OUTCOMES: Extensive data from many randomised, controlled trials have shown the benefit of treating hypertension (HTN). The target blood pressure (BP) for antihypertensive management is systolic < 140 mmHg and diastolic < 90 mmHg, with minimal or no drug side effects. Lower targets are no long...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Clinics Cardive Publishing
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4327181/ https://www.ncbi.nlm.nih.gov/pubmed/25629715 http://dx.doi.org/10.5830/CVJA-2014-062 |
_version_ | 1782357026687418368 |
---|---|
author | Seedat, YK Rayner, BL Veriava, Yosuf |
author_facet | Seedat, YK Rayner, BL Veriava, Yosuf |
author_sort | Seedat, YK |
collection | PubMed |
description | OUTCOMES: Extensive data from many randomised, controlled trials have shown the benefit of treating hypertension (HTN). The target blood pressure (BP) for antihypertensive management is systolic < 140 mmHg and diastolic < 90 mmHg, with minimal or no drug side effects. Lower targets are no longer recommended. The reduction of BP in the elderly should be achieved gradually over one month. Co-existent cardiovascular (CV) risk factors should also be controlled. BENEFITS: Reduction in risk of stroke, cardiac failure, chronic kidney disease and coronary artery disease. RECOMMENDATIONS: Correct BP measurement procedure is described. Evaluation of cardiovascular risk factors and recommendations for antihypertensive therapy are stipulated. Lifestyle modification and patient education are cornerstones of management. The major indications, precautions and contra-indications are listed for each antihypertensive drug recommended. Drug therapy for the patient with uncomplicated HTN is either mono- or combination therapy with a low-dose diuretic, calcium channel blocker (CCB) and an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB). Combination therapy should be considered ab initio if the BP is ≥ 160/100 mmHg. In black patients, either a diuretic and/or a CCB is recommended initially because the response rate is better compared to an ACEI. In resistant hypertension, add an alpha-blocker, spironolactone, vasodilator or β-blocker. VALIDITY: The guideline was developed by the Southern African Hypertension Society 2014©. |
format | Online Article Text |
id | pubmed-4327181 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Clinics Cardive Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-43271812015-04-10 South African hypertension practice guideline 2014 Seedat, YK Rayner, BL Veriava, Yosuf Cardiovasc J Afr Review Article OUTCOMES: Extensive data from many randomised, controlled trials have shown the benefit of treating hypertension (HTN). The target blood pressure (BP) for antihypertensive management is systolic < 140 mmHg and diastolic < 90 mmHg, with minimal or no drug side effects. Lower targets are no longer recommended. The reduction of BP in the elderly should be achieved gradually over one month. Co-existent cardiovascular (CV) risk factors should also be controlled. BENEFITS: Reduction in risk of stroke, cardiac failure, chronic kidney disease and coronary artery disease. RECOMMENDATIONS: Correct BP measurement procedure is described. Evaluation of cardiovascular risk factors and recommendations for antihypertensive therapy are stipulated. Lifestyle modification and patient education are cornerstones of management. The major indications, precautions and contra-indications are listed for each antihypertensive drug recommended. Drug therapy for the patient with uncomplicated HTN is either mono- or combination therapy with a low-dose diuretic, calcium channel blocker (CCB) and an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB). Combination therapy should be considered ab initio if the BP is ≥ 160/100 mmHg. In black patients, either a diuretic and/or a CCB is recommended initially because the response rate is better compared to an ACEI. In resistant hypertension, add an alpha-blocker, spironolactone, vasodilator or β-blocker. VALIDITY: The guideline was developed by the Southern African Hypertension Society 2014©. Clinics Cardive Publishing 2014 /pmc/articles/PMC4327181/ /pubmed/25629715 http://dx.doi.org/10.5830/CVJA-2014-062 Text en Copyright © 2010 Clinics Cardive Publishing http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Seedat, YK Rayner, BL Veriava, Yosuf South African hypertension practice guideline 2014 |
title | South African hypertension practice guideline 2014 |
title_full | South African hypertension practice guideline 2014 |
title_fullStr | South African hypertension practice guideline 2014 |
title_full_unstemmed | South African hypertension practice guideline 2014 |
title_short | South African hypertension practice guideline 2014 |
title_sort | south african hypertension practice guideline 2014 |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4327181/ https://www.ncbi.nlm.nih.gov/pubmed/25629715 http://dx.doi.org/10.5830/CVJA-2014-062 |
work_keys_str_mv | AT seedatyk southafricanhypertensionpracticeguideline2014 AT raynerbl southafricanhypertensionpracticeguideline2014 AT veriavayosuf southafricanhypertensionpracticeguideline2014 |